US 12,472,191 B2
Pharmaceutical formulation for the treatment of inflammatory changes to the rectum
Rudolf Wilhelm, Bischweier (DE); Markus Pröls, Freiburg/Breisgau (DE); Roland Greinwald, Kenzingen (DE); and Ralf Mohrbacher, Freiburg (DE)
Assigned to Dr. Falk Pharma GmbH, Freiburg (DE)
Filed by Dr. Falk Pharma GmbH, Freiburg (DE)
Filed on Jul. 12, 2023, as Appl. No. 18/221,164.
Application 18/221,164 is a continuation of application No. 17/094,233, filed on Nov. 10, 2020, granted, now 11,738,032.
Application 17/094,233 is a continuation of application No. 15/742,710, granted, now 10,905,699, issued on Feb. 2, 2021, previously published as PCT/EP2016/064907, filed on Jun. 28, 2016.
Claims priority of application No. 15175806 (EP), filed on Jul. 8, 2015.
Prior Publication US 2023/0364113 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 37/00 (2006.01); A01N 25/00 (2006.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); A61K 9/02 (2006.01); A61K 31/215 (2006.01); A61K 31/24 (2006.01); A61K 31/58 (2006.01); A61K 31/606 (2006.01); A61P 29/00 (2006.01)
CPC A61K 31/58 (2013.01) [A61K 9/02 (2013.01); A61K 31/606 (2013.01); A61P 29/00 (2018.01)] 17 Claims
 
1. A pharmaceutical formulation for rectal administration, containing budesonide or pharmaceutically compatible salt or derivative thereof; at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, at least one anti-oxidation agent comprising ascorbyl palmitate, wherein the budesonide is present in a micronized form, wherein 100% of the particles are smaller than 10 μm per particle.